We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma.
- Authors
Kojima, Yuki; Shimoi, Tatsunori; Seo, Takuji; Yazaki, Shu; Okuya, Toshihiro; Ohtake, Yohei; Okuma, Hitomi S.; Shimomura, Akihiko; Nishikawa, Tadaaki; Tanioka, Maki; Sudo, Kazuki; Noguchi, Emi; Tamura, Kenji; Yoshida, Akihiko; Iwata, Shintaro; Kobayashi, Eisuke; Kawai, Akira; Fujiwara, Yasuhiro; Yonemori, Kan
- Abstract
Introduction: Synovial sarcoma (SS) predominantly affects adolescents and young adults. Doxorubicin with or without ifosfamide therapy is the standard first-line treatment for unresectable or metastatic SS. However, there is no standard second-line chemotherapy regimen. The purpose of the current study was to evaluate the outcomes of second-line chemotherapy for patients with SS. Methods: We retrospectively evaluated the outcomes of 61 patients with unresectable or metastatic SS who had received first-line chemotherapy at our institution between 1997 and 2017. Patients who received second-line chemotherapy were included in the analysis. Outcomes of the chemotherapy were evaluated. Results: Among the 61 patients treated with first-line chemotherapy, we identified 32 patients who received second-line chemotherapy. Most patients (62.5%) were under 40 years of age. Regarding second-line chemotherapy regimens, 6 (18.8%) patients were treated with doxorubicin with/without ifosfamide, 6 (18.8%) with ifosfamide and etoposide, 4 (12.5%) with docetaxel and gemcitabine, 5 (15.6%) with pazopanib, 2 (6.2%) with trabectedin, and 1 (3.1%) with eribulin. The overall response rate according to the Response Evaluation Criteria in Solid Tumors for all patients was 9.4%. Eleven patients (34.3%) achieved disease-control for >6 months. The median follow-up duration was 15.2 months. The 1-year progression-free and overall survival rates were 33.1% and 67.1%, respectively. Conclusion: Our exploratory study revealed that the response rate of second-line chemotherapy regimens for patients with SS was 9.4%. Therefore, there is an urgent need to develop more active therapeutic regimens for SSs.
- Subjects
RESEARCH; SYNOVIAL membranes; CANCER chemotherapy; RETROSPECTIVE studies; TREATMENT effectiveness; SURVIVAL analysis (Biometry); DESCRIPTIVE statistics; PROGRESSION-free survival; SARCOMA
- Publication
Oncology, 2022, Vol 100, Issue 7, p370
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000524500